NINLARO® For Relapsed Multiple Myeloma - Patient Information
Learn about the NINLARO® (ixazomib) treatment combination for multiple myeloma that has returned that may help you keep an active lifestyle. See Important Safety Information and Prescribing …
NINLARO® (ixazomib) - Official HCP Site
NINLARO in combination with lenalidomide and dexamethasone is an approved treatment for relapsed multiple myeloma after at least 1 previous therapy, including indolent relapsed multiple myeloma. …
Ninlaro (ixazomib) - International Myeloma Foundation
May 23, 2024 · In 2015, the U.S. Food and Drug Administration approved NINLARO® (ixazomib) for the treatment of adult patients with myeloma who have received at least 1 prior therapy. Ninlaro is the …
Ninlaro: Uses, Dosage, Side Effects, Warnings - Drugs.com
May 20, 2025 · Ninlaro is a cancer medicine used to treat multiple myeloma (bone marrow cancer), in combination chemotherapy with lenalidomide and dexamethasone.
Multiple Myeloma Treatments | Drugs & Treatment by Stage - MMRF
There are many options for treating multiple myeloma. Learn more about the different types of treatment and some of the common side effects.
New Therapeutic for Treating Multiple Myeloma | The AACR
Nov 20, 2015 · The new anticancer therapeutic was approved for use in combination with lenalidomide (Revlimid) and dexamethasone. The three-drug treatment regimen is intended for patients with …
Takeda Publishes Promising Trial Results on Ixazomib, an Approved...
Apr 29, 2016 · Takeda Pharmaceutical has published promising data from the TOURMALINE-MM1 Phase 3 clinical trial of patients with relapsed and/or refractory multiple myeloma (MM), treated with …
Ixazomib Treatment Guide - Myeloma UK
Ixazomib Treatment Guide This Treatment Guide contains information about ixazomib, a treatment used in myeloma. This publication is part of our Treatment Guide series, a collection of booklets covering …
The Top Myeloma News of 2025 | Targeted Oncology
4 days ago · Discover the latest breakthroughs in multiple myeloma treatment, including CAR T-cell therapies and promising new options for relapsed patients.
FDA Approves Ninlaro, New Oral Medication to Treat Multiple Myeloma
Ninlaro is the first oral proteasome inhibitor and is approved in combination with another FDA-approved treatment for multiple myeloma called Revlimid (lenalidomide) and dexamethasone (a type of …